维持治疗与延长诱导疗程可改善MGRS患者无复发生存
该回顾性多中心研究分析了50例活检证实的MGRS患者,最常见病理为单克隆免疫球蛋白沉积性增殖性肾小球肾炎(72%)。中位随访6.15年,浆细胞导向治疗组中位无复发生存(RFS)为3.74年,B细胞导向组为19年;维持治疗和诱导疗程>6个月与RFS显著改善相关,多因素分析仍显著。
要点
- MGRS患者中维持治疗与诱导疗程>6个月与RFS显著改善独立相关。
- 浆细胞导向治疗组中位RFS为3.74年,B细胞导向组为19年。
- 诱导方案类型或自体干细胞移植(ASCT)与RFS和总生存(OS)无显著差异。
核心结论
- 维持治疗和延长治疗疗程可能改善MGRS患者的疾病控制。
- 支持进一步评估延长治疗策略以预防肾损伤并改善长期结局。
研究设计与样本
- 回顾性分析3家机构活检证实的50例MGRS患者。
- 37例接受浆细胞导向治疗,8例接受B细胞导向治疗。
主要发现
- 最常见组织病理诊断为单克隆免疫球蛋白沉积性增殖性肾小球肾炎(72%)。
- 中位估算肾小球滤过率为32 mL/min(四分位距17-51),中位24小时蛋白尿为3.28 g。
- 中位随访6.15年,浆细胞导向治疗组中位RFS为3.74年,B细胞导向组为19年。
- 浆细胞导向治疗组中,RFS和OS按诱导方案或ASCT使用无显著差异。
- 维持治疗和诱导疗程>6个月与RFS显著改善相关,多因素分析仍显著。
关键数值与推荐
- 浆细胞导向诱导方案包括达雷妥尤单抗为基础方案(32.4%)、CyBorD(29.7%)和硼替佐米-地塞米松(29.7%)。
- 37例浆细胞导向治疗患者中13例(35.1%)接受维持治疗。
临床怎么用
- 对MGRS患者可考虑维持治疗和延长诱导疗程以改善无复发生存。
- 诱导方案选择和ASCT使用与RFS和OS无显著相关,需个体化决策。
局限性
- 回顾性设计且样本量小(50例),可能存在选择偏倚。
- MGRS罕见,需更大规模研究验证延长治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity with multiple therapeutic approaches, often modeled after therapies used for multiple myeloma, including anti-CD38 antibodies, proteasome inhibitors, immunomodulatory agents, and autologous stem cell transplantation (ASCT). However, because of its rarity, the optimal use of newer agents, ASCT, and maintenance therapy remains poorly defined. We retrospectively analyzed 50 patients with biopsy-proven MGRS treated across 3 institutions. The most common histopathologic diagnosis was proliferative glomerulonephritis with monoclonal immunoglobulin deposits (72%). Median estimated glomerular filtration rate was 32 mL/min (interquartile range, 17-51), and median 24-hour proteinuria was 3.28 g. A total of 37 patients received plasma cell (PC)-directed therapy, and 8 patients received B-cell-directed therapy. Common PC-directed induction regimens included daratumumab-based therapy (32.4%), CyBorD (cyclophosphamide, bortezomib, and dexamethasone; 29.7%), and bortezomib-dexamethasone (29.7%). Maintenance therapy was administered to 13 of 37 treated patients in the PC group (35.1%). With a median follow-up of 6.15 years, the median relapse-free survival (RFS) was 3.74 years in the PC group and 19 years in the B-cell group. Among PC-treated patients, RFS and overall survival (OS) did not significantly differ by induction regimen or use of ASCT. In contrast, maintenance therapy and induction duration >6 months were associated with significantly improved RFS, which remained significant on multivariate analysis. These findings suggest that maintenance therapy and prolonged treatment duration may improve disease control in MGRS and support further evaluation of extended treatment strategies to prevent renal damage and improve long-term outcomes.
引用
- Cottini F, Iyer S, Avila-Rodriguez A, et al. Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance. Blood Adv. 2026. PMID: 42418393. doi:10.1182/bloodadvances.2025018896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。